Related Experiment Video
Updated: Dec 19, 2025
Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain
Published on: October 3, 2012
[Effects of SGI-1027 on Formation and Elimination of PrP^(Sc) in Prion-Infected Cells]
J J Li1, C S Ryou2, D-H Kim3,4
1Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju, 61005 Republic of Korea.
Abstract:
Recently, SGI-1027, a well-known inhibitor of DNA-methyl transferases (DNMTs), was reported to effectively reduce formation of pathogenic PrP^(Sc) in prion-infected cells. Herein, we confirm the elimination of PrP^(Sc) in chronic wasting disease (CWD) prion-infected neurons by SGI-1027, and pinpoint the binding region of human prion protein to SGI-1027. SGI-1027 is broadly functional against various prion disease types, including human prions. Previously, the inhibitory effects of SGI-1027 on DNMT function is well tested in various cell culture models. While neither treatment with a DNMTs enhancer S-adenosyl-L-methionine (SAM), nor with their inhibitor, 5-azacytidine, prevented PrP^(Sc) propagation, SGI-1027 did. Our study suggest that the anti-prion effects of SGI-1027 are a result of its direct interaction with PrP^(C), which effectively interferes with the pathogenic conformational change of PrP^(C) to PrP^(Sc). We conclude that SGI-1027 driven suppression of pathogenic PrP^(Sc) is independent of DNMT.
Insights
SGI-1027 eliminates pathogenic prion protein (PrPSc) in prion-infected cells, including chronic wasting disease models. This anti-prion effect stems from direct interaction with the cellular prion protein (PrPC), not DNA methyltransferase inhibition.
Area of Science:
- Neuroscience
- Biochemistry
- Molecular Biology
Background:
- Prion diseases are fatal neurodegenerative disorders characterized by the accumulation of misfolded prion proteins (PrPSc).
- SGI-1027, a known DNA methyltransferase (DNMT) inhibitor, has shown potential in reducing PrPSc formation.
- The precise mechanism of SGI-1027's anti-prion activity remains to be fully elucidated.
Purpose of the Study:
- To confirm the efficacy of SGI-1027 in eliminating PrPSc in chronic wasting disease (CWD) models.
- To identify the specific binding site of SGI-1027 on the human prion protein.
- To determine whether SGI-1027's anti-prion effects are mediated through DNMT inhibition.
Main Methods:
- Treatment of CWD prion-infected neurons with SGI-1027.
- Identification of SGI-1027 binding regions on human prion protein.
- Comparative studies using DNMT enhancer (SAM) and inhibitor (5-azacytidine).
Main Results:
- SGI-1027 effectively eliminated PrPSc in CWD-infected neurons.
- The binding region of human prion protein to SGI-1027 was identified.
- SGI-1027 demonstrated broad efficacy against various prion types, including human prions.
- Neither SAM nor 5-azacytidine affected PrPSc propagation, indicating SGI-1027's action is independent of DNMTs.
Conclusions:
- SGI-1027 effectively suppresses pathogenic PrPSc formation in prion diseases.
- The anti-prion mechanism of SGI-1027 involves direct interaction with cellular prion protein (PrPC).
- This interaction interferes with the conformational conversion of PrPC to PrPSc, independent of DNMT activity.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
01:29Subviral Agents